Entasis Therapeutics - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsEntasis Therapeutics

Entasis Therapeutics(ETTX)

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

*Currency in USD

Company Revenue

Quarterly

Quarterly

Annual

Annual

Projections

*Quarterly sales USD (in millions)

Plot placeholder

Mock data
Subscribe for the real data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Xacduro	Sulbactam, Durlobactam	2023-05-23	2033-2035	Respiratory tract infections , Urinary tract infections , Pneumococcal infections , Infectious pregnancy complications , Bacterial infections , Gonorrhea , Intraabdominal infections , Bacterial skin diseases , Escherichia coli infections , Soft tissue infections , Bacillary dysentery , Surgical wound infection , Staphylococcal infections , Bacterial endocarditis , Bacterial meningitis , Salmonella infections , Proteus infections , Acinetobacter infections , Listeriosis , Klebsiella infections , Meningococcal infections , Haemophilus infections , Human bites , Actinomycosis

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

bacterial pneumonia

,

,

,

communicable diseases

,

,

,

wound infection

,

,

abdominal abscess

,

,

healthy volunteers/patients

,

,

renal insufficiency

,

healthy volunteers/patients

,

urinary tract infections

,

,

acinetobacter infections

,

ventilator-associated pneumonia

,

iatrogenic disease

,

Cephalosporin c

bacterial infections

healthy volunteers/patients

renal insufficiency

,

delayed graft function

,

hereditary angioedemas

,

hereditary nephritis

healthy volunteers/patients

,

chronic kidney failure

,

kidney diseases

,

healthy volunteers/patients

,

,

kidney diseases

,

retinal diseases

,

,

non-small-cell lung carcinoma

,

,

large-cell lymphoma anaplastic

,

respiratory syncytial virus infections

,

pulmonary arterial hypertension

,

breast neoplasms

,

,

endometrial neoplasms

,

,

brain neoplasms

,

gram-negative bacterial infections

,

urinary tract infections

,

bacterial infections

,

wound infection

,

,

bacterial pneumonia

,

infectious skin diseases

,

soft tissue infections

,

,

healthcare-associated pneumonia

,

,

nontuberculous mycobacterium infections

,

chronic bronchitis

,

,

,

,

,

,

mycobacterium infections

,

community-acquired infections

,

,

gram-positive bacterial infections

,

,

,

communicable diseases

,

intraabdominal infections

,

mycobacterium avium-intracellulare infection

,

mycobacterium avium complex

,

,

,

,

,

ventilator-associated pneumonia

,

methicillin-resistant staphylococcus aureus

,

,

acute necrotizing pancreatitis

,

community-acquired pneumonia

,

,

,

,

abdominal abscess

,

renal insufficiency

,

,

urinary tract infections

,

,

,

,

,

,

,

,

bacterial conjunctivitis

,

,

,

corneal diseases

,

cataract extraction

,

macular degeneration

,

intravitreal injections

,

endophthalmitis

Fluoroquinolone

healthy volunteers/patients

,

,

,

communicable diseases

,

,

bacterial conjunctivitis

,

bacterial eye infections

,

cataract extraction

,

corneal diseases

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use